Literature DB >> 472724

3-Methoxy-4-hydroxyphenethyleneglycol production by human brain in vivo.

J W Maas, S E Hattox, N M Greene, D H Landis.   

Abstract

A direct method has been employed to estimate the rate of production by human brain of 3-methoxy-4-hydroxyphenethyleneglycol, the major metabolite of brain norepinephrine, a brain neurotransmitter. Venous specimens were obtained from the internal jugular vein from ten awake human subjects at a puncture site above the common facial vein, the first major source of extracranial inflow. Arterial specimens were simultaneously obtained from the radial artery. Plasma samples were assayed and a highly significant difference was found in the concentration of the metabolite in plasma coming out of the brain (venous blood) as compared to plasma entering the brain (arterial blood). This venous-arterial difference was calculated to be 0.7 +/- 0.1 nanogram per milliliter of blood. Assuming an adult brain weight of 1400 grams and normal cerebral blood flow, it is estimated that the rate of production of 3-methoxy-4-hydroxyphenethyleneglycol by the awake human brain is approximately 597 nanograms per minute or 35.8 micrograms per hour. Urine specimens were also collected from six of these subjects during a period of 1 to 3.5 hours, which bracketed the time the blood samples were obtained. For these six subjects the output of 3-methyoxy-4-hydroxyphenethyleneglycol by whole brain was estimated to be 40.9 micrograms per hour, whereas the rate of its excretion into urine was 64.5 micrograms per hour.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 472724     DOI: 10.1126/science.472724

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  14 in total

Review 1.  Urinary MHPG sulfate as a marker of central norepinephrine metabolism: a commentary.

Authors:  L Peyrin
Journal:  J Neural Transm Gen Sect       Date:  1990

2.  A simplified routine assay for urinary 3-methoxy-4-hydroxyphenylglycol.

Authors:  J K Yao; P Zhu; D J Wilds; D P van Kammen
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  MHPG excretion in endogenous depression: relationship to clinical state and the effects of ECT.

Authors:  M H Joseph; D Risby; T J Crow; J F Deakin; E C Johnstone; P Lawler
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Sulfate and glucuronide conjugates of 3-methoxy-4-hydroxyphenylglycol (MHPG) in urine of depressed patients: central and peripheral influences.

Authors:  L Peyrin; J M Pequignot; G Chauplannaz; B Laurent; G Aimard
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

5.  Toward a biochemical classification of depressive disorders. III: Pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline.

Authors:  A F Schatzberg; A H Rosenbaum; P J Orsulak; W A Rohde; T Maruta; E R Kruger; J O Cole; J J Schildkraut
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  Acathisia-syndrome: involvement of noradrenergic mechanisms.

Authors:  M Bartels; H J Gaertner; G Golfinopoulos
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

7.  Norepinephrine and impulsivity: effects of acute yohimbine.

Authors:  Alan C Swann; Marijn Lijffijt; Scott D Lane; Blake Cox; Joel L Steinberg; F Gerard Moeller
Journal:  Psychopharmacology (Berl)       Date:  2013-04-06       Impact factor: 4.530

8.  Urinary free and conjugated catecholamines and metabolites in autistic children.

Authors:  C Barthelemy; N Bruneau; J M Cottet-Eymard; J Domenech-Jouve; B Garreau; G Lelord; J P Muh; L Peyrin
Journal:  J Autism Dev Disord       Date:  1988-12

9.  Amphetamine withdrawal: effects on threshold of intracranial reinforcement.

Authors:  G Cassens; C Actor; M Kling; J J Schildkraut
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Dopamine-beta-hydroxylase (DBH) and homovanillic acid (HVA) in autistic children.

Authors:  C Garnier; E Comoy; C Barthelemy; I Leddet; B Garreau; J P Muh; G Lelord
Journal:  J Autism Dev Disord       Date:  1986-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.